Loading...

STRZ

ZN

ASTRAZENECA PLC

(AZN)

2025 6-K

Positive Trial Results

31 Mar '26

Clinical Trial Success

27 Mar '26

Share Admission Notification

20 Mar '26

EU Approval Granted

16 Mar '26

AGM Notice

10 Mar '26

AGM Notice 2026

10 Mar '26

Director Shareholding

6 Mar '26

Share Vesting Report

6 Mar '26

Share Awards Granted

6 Mar '26

Debt Issuance

2 Mar '26

Voting Rights Update

2 Mar '26

Bond Offering

26 Feb '26

Annual Report Filed

25 Feb '26

AstraZeneca Filing

24 Feb '26

Annual Financial Report

24 Feb '26

Board Changes

24 Feb '26

Calquence Approval

20 Feb '26

Financial Results Summary

10 Feb '26

Saphnelo Update

3 Feb '26

Voting Rights Update

2 Feb '26

Imfinzi Approval Recommenda...

2 Feb '26

NYSE Listing Start

2 Feb '26

AstraZeneca CSPC Deal

30 Jan '26

AstraZeneca Investment

29 Jan '26

Direct Listing NYSE

20 Jan '26

Management Change

8 Jan '26

Voting Rights Update

2 Jan '26

Director Sale

22 Dec '25

FDA Breakthrough Designation

22 Dec '25

Trial Update

22 Dec '25

Share Gift Notification

19 Dec '25

Saphnelo Approved

16 Dec '25

Enhertu FDA Approval

16 Dec '25

Holding Update

4 Dec '25

Block Listing Update

1 Dec '25

Voting Rights Update

1 Dec '25

Imfinzi Approval

26 Nov '25

Koselugo Approval

20 Nov '25

Voting Rights Update

17 Nov '25

Director Shareholding

14 Nov '25

CEO Share Transfer

10 Nov '25

Strong Financial Growth

6 Nov '25

General Meeting Results

3 Nov '25

Voting Rights Update

3 Nov '25

Corporate Filing Update

3 Nov '25

Director Appointment

28 Oct '25

Koselugo Approved

28 Oct '25

Tezspire EU Approval

22 Oct '25

Tezspire Approved

20 Oct '25

Positive CHMP Opinion

20 Oct '25

Medicine Price Agreement

14 Oct '25

Baxdrostat Trial Success

7 Oct '25

Datroway Milestone

6 Oct '25

Voting Rights Update

1 Oct '25

Enhertu Trial Success

29 Sep '25

Listing Structure Update

29 Sep '25

Harmonised Listing Proposal

29 Sep '25

Shareholding Update

25 Sep '25

EU Approval Recommendation

22 Sep '25

EU Approval Recommendation

22 Sep '25

Saphnelo Success

17 Sep '25

Trial Update

17 Sep '25

Voting Rights Update

2 Sep '25

Correction Notice

28 Aug '25

Voting Rights Update

26 Aug '25

Major Holdings Update

21 Aug '25

Shareholding Update

18 Aug '25

Major Holdings Update

15 Aug '25

Major Holdings Update

12 Aug '25

Voting Rights Update

1 Aug '25

Company Update

29 Jul '25

Positive Trial Results

24 Jul '25

Major Investment Announcement

22 Jul '25

Anselamimab Update

16 Jul '25

Baxdrostat Trial Success

14 Jul '25

EU Approval Granted

7 Jul '25

Voting Rights Update

1 Jul '25

FDA Approval Announcement

24 Jun '25

Collaboration Agreement

13 Jun '25

Share Donation

12 Jun '25

Calquence Approval

6 Jun '25

Block Listing Review

2 Jun '25

Voting Rights Update

2 Jun '25

EU Approval Update

27 May '25

Share Vesting Update

23 May '25

Director Appointment

21 May '25

Acquisition Complete

20 May '25

Imfinzi Trial Success

9 May '25

Enhertu's Efficacy

7 May '25

Calquence Approved

6 May '25

Breztri Phase III Results

2 May '25

Management Purchase

1 May '25

Voting Rights Update

1 May '25

Calquence EU Approval

29 Apr '25

Trial Discontinuation

29 Apr '25

Q1 Results Growth

29 Apr '25

Clinical Trial Update

22 Apr '25

AGM Results Announced

11 Apr '25

Imfinzi Approved

4 Apr '25

EU Approves Enhertu

4 Apr '25

Voting Rights Update

1 Apr '25

EU Approval Update

31 Mar '25

Imfinzi Approval

31 Mar '25

Major Investment

21 Mar '25

Trial Success

17 Mar '25

EU Approval Granted

17 Mar '25

Acquisition Announcement

17 Mar '25

Voting Rights Update

12 Mar '25

Share Vesting Notification

7 Mar '25

AGM Notice Issued

7 Mar '25

Imfinzi Trial Results

7 Mar '25

AGM Announcement

7 Mar '25

Share Vesting Notification

6 Mar '25

Share Awards Granted

5 Mar '25

Voting Rights Update

3 Mar '25

EU Approval Recommendation

3 Mar '25

EU Approval Recommendation

28 Feb '25

Camizestrant Progress

26 Feb '25

Annual Report Filing

19 Feb '25

Form 6-K Filing

18 Feb '25

Major Shareholding Update

18 Feb '25

Annual Report Filing

18 Feb '25

Board Changes

18 Feb '25

Strong FY 2024 Results

6 Feb '25

Voting Rights Report

3 Feb '25

EU Approval Update

3 Feb '25

Enhertu Approval

28 Jan '25

FDA Approval News

21 Jan '25

Calquence Approval

17 Jan '25

Voting Rights Update

2 Jan '25

Application Withdrawn

26 Dec '24

Tagrisso Approval

23 Dec '24

Board Appointments

16 Dec '24

Imfinzi Approval

5 Dec '24

Executive Appointment

4 Dec '24

Block Listing Update

2 Dec '24

Voting Rights Update

2 Dec '24

Positive Trial Results

25 Nov '24

Director Share Purchase

20 Nov '24

Tagrisso EU Approval

18 Nov '24

Director Share Purchase

15 Nov '24

CEO Shares Purchase

15 Nov '24

Director Share Purchase

13 Nov '24

$3.5 Billion Investment

12 Nov '24

KOMET Trial Results

12 Nov '24

Financial Results Update

12 Nov '24

New BLA Submitted

12 Nov '24

Tezspire Trial Results

8 Nov '24

Voting Rights Update

1 Nov '24

Investigation Alert

30 Oct '24

EU Approval Update

21 Oct '24

Cardiovascular Asset License

7 Oct '24

Voting Rights Update

1 Oct '24

Tagrisso Approval

26 Sep '24

EU Approval Recommendation

23 Sep '24

TROPION-Breast01 Results

23 Sep '24

FluMist Approval

20 Sep '24

FDA Approval Fasenra

18 Sep '24

Share Purchase Update

13 Sep '24

Voting Rights Update

3 Sep '24

Imfinzi Approval

16 Aug '24

Voting Rights Update

1 Aug '24

Bond Offering

30 Jul '24

CLL Treatment Update

29 Jul '24

Imfinzi Review

26 Jul '24

Quarterly Update

25 Jul '24

AstraZeneca Acquisition

15 Jul '24

Voting Rights Update

1 Jul '24

EU Drug Approval

1 Jul '24

Trial Results Update

25 Jun '24

Imfinzi Trial Results

25 Jun '24

Trial Outcome Update

18 Jun '24

Imfinzi Approval News

17 Jun '24

Share Gift Notification

12 Jun '24

Fusion Acquisition

4 Jun '24

Interim Review Summary

3 Jun '24

Voting Rights Update

3 Jun '24

EU Approval Recommendation

3 Jun '24

Lung Cancer Progress

28 May '24

Revenue Target Announcement

21 May '24

New Manufacturing Facility

20 May '24

COVID-19 Trial Success

16 May '24

Share Award Grant

15 May '24

Investment Completion

7 May '24

Positive Trial Results

2 May '24

Voting Rights Update

1 May '24

EU Approval Recommended

29 Apr '24

Enhertu Trial Results

29 Apr '24

First Quarter Growth

25 Apr '24

AGM Voting Results

11 Apr '24

Dividend Increase

11 Apr '24

Enhertu Approval

8 Apr '24

Imfinzi Success

5 Apr '24

Voting Rights Update

2 Apr '24

Voydeya Approved

2 Apr '24

FDA Acceptance Announcement

2 Apr '24

Ultomiris Approval

25 Mar '24

AstraZeneca Acquisition

19 Mar '24

AstraZeneca Acquisition

14 Mar '24

Share Vesting Announcement

12 Mar '24

Annual General Meeting

7 Mar '24

AGM Notification

7 Mar '24

Share Award Vested

6 Mar '24

Director Share Awards

6 Mar '24

EMA Validation Announcement

4 Mar '24

Voting Rights Update

1 Mar '24

Debt Issuance Update

26 Feb '24

EU Approval Recommended

26 Feb '24

Bond Offering Announcement

22 Feb '24

Gracell Acquisition

22 Feb '24

Share Vesting Report

22 Feb '24

Annual Report Filing

21 Feb '24

Annual Filing Report

20 Feb '24

Annual Report Filing

20 Feb '24

Icosavax Acquisition

20 Feb '24

Icosavax Acquisition

20 Feb '24

FDA Approval Announcement

20 Feb '24

FDA Acceptance

20 Feb '24

Tagrisso Progress

20 Feb '24

Financial Performance

8 Feb '24

Total Voting Rights

1 Feb '24

Acquisition Update

19 Jan '24

Voting Rights Update

2 Jan '24

External Links:

SEC

AstraZeneca's Imfinzi has been approved in the US as the first and only perioperative immunotherapy for early gastric cancer, based on data from the MATTERHORN Phase III trial conducted until November 2025. The treatment shows a 29% reduced risk of disease progression and a 22% decrease in mortality compared to chemotherapy alone, making it a significant development for patients with this type of cancer.

AI Assistant

ASTRAZENECA PLC

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.